Scienture Holdings, Inc. (SCNX) is transitioning from a diversified platform into a focused, commercial-stage specialty pharmaceutical company centered on its wholly owned subsidiary, Scienture, LLC. The company's investment thesis is characterized by high-potential niche product launches offset by severe near-term liquidity constraints and going concern risks. Scienture's first FDA-approved product, ARBLI™ (the first ready-to-use liquid formulation of losartan), launched in 2025 and is gaining commercial traction, supported by expanded payer coverage of over 112.5 million covered lives. Its second product, REZENOPY™ (a high-dose 10 mg naloxone nasal spray), is scheduled for commercial launch in mid-July 2026 with established formulary coverage. However, the company's current financial profile is highly leveraged and cash-constrained. In Q1 2026, Scienture generated only $56,325 in revenue against $3.56 million in operating expenses, resulting in a net loss of $3.4 million. With cash reserves at $3.54 million as of March 31, 2026, and substantial doubt regarding its ability to continue as a going concern, the company remains highly dependent on rapid commercial execution and additional financing. Consequently, a Hold recommendation is advised until commercial revenues scale sufficiently to offset the high operating cash burn.